Is this page for you?
Tick everything that applies. CAR-T is only an option for certain cancers and certain targets — if several of these apply, a free case review can tell you whether you actually qualify and at which hospital.
How CAR-T works here
This is the typical sequence at a Chinese center with an established cell-therapy programme. Your own timeline is set by the treating team after they review your records.
Illustrative pathway — your actual plan is determined by the hospital's cell-therapy team, not by this page.
Case review & eligibility
Pathology, imaging and treatment history are reviewed against the product's indication. Target-antigen testing (CD19, BCMA or Claudin18.2) has to be confirmed before anything else.
Apheresis
Your T cells are collected by leukapheresis, usually over one or two sessions, and shipped to the manufacturing site.
The waiting window
The cells are engineered and expanded — typically two to four weeks. Bridging treatment may be needed so the disease stays controlled during this window.
Lymphodepletion & infusion
A short course of chemotherapy (usually fludarabine and cyclophosphamide) prepares your body, then the engineered cells are infused.
Inpatient monitoring
About ten to fourteen days of close observation for cytokine release syndrome and neurological side effects, followed by remote follow-up after you return home.
Routes of access
There are two genuinely different routes in China, and they are not interchangeable. Which one applies to you depends on your cancer type and how much treatment you have already had.
Approved CD19 CAR-T
Approved BCMA CAR-T
Satri-cel (solid tumor)
Clinical trial CAR-T
What the evidence actually shows
The clearest published data in this field comes from the satri-cel Phase 2 trial (CT041-ST-01), reported in The Lancet. These are the numbers as published — not a forecast for any individual patient.
About 15% of patients in the satri-cel arm never received the infusion, because the disease progressed or their condition declined during the manufacturing window. Among patients who did receive the cells, median progression-free survival was 4.37 vs 1.84 months.
An objective response means the tumor shrank measurably — it is not the same as a cure. A hazard ratio describes relative risk across a group, not a guarantee for an individual. Response varies by patient and requires long-term follow-up.
Hospitals we would look at first
Selected for oncology ranking, haematology capability and cell-therapy experience — not by commission. We confirm which of these can actually take your case before you commit to anything.
Reference costs
Reference ranges for treatment in China. Final quotes come from the hospital after your records and target testing are reviewed — and the itemisation matters as much as the headline number.
| Route | Reference cost (China) | Notes |
|---|---|---|
| Approved CD19 or BCMA CAR-T | $89,000–$170,000 | drug plus the full treatment course |
| Satri-cel (gastric / GEJ) | $89,000–$170,000 | approved product, quoted per case |
| Clinical trial participation | ≈$30,000–$80,000 | varies by trial; some costs covered |
| Travel, accommodation, monitoring | ≈$3,500–$10,500 | excluding the drug, for a 4–6 week stay |
Prices are reference ranges and change frequently. Confirm whether a hospital's quote includes tocilizumab, ICU standby and the full post-infusion monitoring period — these are sometimes billed separately.
What CAR-T is not
- It is not a cure, and it is not for everyone. CAR-T has produced durable remissions in some blood cancers, but response depends heavily on cancer type, target and how much treatment you have already had.
- It carries real risk. Cytokine release syndrome and neurological toxicity are expected complications, not rare ones, and they require an experienced team with intensive-care backup.
- Solid-tumor CAR-T is still early. Satri-cel's approval is a genuine milestone, but the published survival benefit is measured in months, not years. Any clinic promising a cure for a fee is not operating within the approved framework.
- A screening response is not an approval for treatment. Eligibility is confirmed by the hospital's own team after records and target testing are reviewed.
- We do not sell the treatment. We coordinate and translate. Hospital treatment costs are paid directly to the hospital, and we take no commission from any hospital.
Frequently asked questions
Am I eligible for CAR-T therapy in China?
Eligibility depends on your cancer type, how many prior treatments have failed, and the target antigen on your tumor. In general, patients must have progressed after standard therapy, have adequate heart, liver and kidney function, no active infection, and no cancer spread to the central nervous system. A free case review with your records and a tissue sample confirms whether you qualify.
How much does CAR-T cost in China?
Reference ranges for commercial CAR-T are roughly $89,000 to $170,000 for the drug plus the full treatment course, depending on the product and hospital. Clinical trial participation typically runs $30,000 to $80,000, and some trials cover part of the cost. Confirm whether a quote includes tocilizumab, ICU standby and the full post-infusion monitoring period, which are sometimes billed separately.
Is CAR-T a cure?
No. CAR-T has produced durable remissions in some blood cancers, but it is not a cure and it is not suitable for everyone. Response rates are reported at group level — an objective response means the tumor shrank measurably, not that the cancer is gone. CAR-T also carries real risks, including cytokine release syndrome and neurological toxicity, which is why it must be managed by an experienced team.
What is the difference between approved CAR-T and a clinical trial?
Approved CAR-T products have cleared NMPA review for a defined indication, and the hospital can offer them as standard care. A clinical trial gives access to a product that is not yet approved — it may be more effective for your case, but outcomes are more uncertain and screening criteria are stricter. Both routes are available in China, but they are not interchangeable.
How long do I need to stay in China?
Most international patients need to plan for roughly four to six weeks in China. The sequence covers case review, apheresis, a manufacturing window of about two to four weeks, lymphodepleting chemotherapy, the infusion itself, and inpatient monitoring for about ten to fourteen days.
Find out whether CAR-T is real for your case
Send us your diagnosis, pathology report and treatment history. We'll tell you whether an approved product or a trial is worth pursuing for your cancer type, which hospitals to approach, and what it would realistically cost — free, with no obligation to go further.
Start Free Case Review →